Johns Hopkins POC-IT: Point of Care Information Technology [Home]
HIV Guide
 Zambia HIV National Guidelines
 


Introduction  

HIV Counseling and Testing  

Sexually Transmitted Infections (STIs)  

General Principles of Antiretroviral Therapy for Chronic HIV Infection in Adults and Adolescents  

When to Start ARV Therapy for Chronic HIV Infection in Adults and Adolescents  

Initial Regimen for ARV Therapy  

Adherence  

Baseline evaluation and Monitoring  

Calculations: Ideal Body Weight, Body Mass Index and Creatinine Clearance  

ARV Therapy for Individuals with Tuberculosis Co-Infection  

Adverse Effects and Toxicity  

Immune Reconstitution Inflammatory Syndrome (IRIS)  

Changing or Stopping ART  

Treatment Failure  

Stopping ARV Therapy  

Post Exposure Prophylaxis  

Cotrimoxazole Prophylaxis  

WHO Staging in Adults and Adolescents  

Nutrition Care and Support  

Palliative Care in HIV and AIDS  

 Guide Editors
 Editor In Chief
    Joel E. Gallant, MD, MPH

Pharmacology Editor
    Paul Pham, PharmD, BCPS

Zambia Guideline Team
   Peter Mwaba MMed PhD FRCP
   Alywn Mwinga MMed
   Isaac Zulu MMed MPH
   Velepie Mtonga MMed
   Albert Mwango MBChB
   Jabbin Mulwanda MMed FCS
 

 

 

Drugs>Antimicrobial Agents>
HIV Guide Home PageEmail this module to a friend

Amphotericin B

Paul A. Pham Pharm.D. and John G. Bartlett M.D.
09-12-2008

Zambia Specific Information

  • Available formulation in Zambia: Powder for injection: 50 mg in vial.
  • Gold standard for most deep-seated mycotic infections.
  • Cryptococcal meningitis: amphotericin 0.7 mg/kg/d x 14 days (induction). If renal failure, fluconazole 800 mg x1, then 400 mg daily can be considered, but has been shown to be suboptimal during induction phase.
  • Esophageal candidiasis resistant to fluconazole: amphoB 0.7 mg/kg/d x 14 days (lower doses 0.3 mg/kg/d can be considered).

REFERENCES

Zambia Information Author: Paul A. Pham Pharm.D.

INDICATIONS

FDA

  • Aspergillosis  
  • Blastomycosis
  • Disseminated candidiasis
  • Leishmaniasis 
  • Cryptococcosis
  •  Histoplasmosis 
  • Cryptococcal meningitis (treatment and suppression)
  • Sporotrichosis; mucromycosis; basidiobolus; conidiobolus
  •  Coccidioidomycosis 
  • Treatment of fungal infections involving the CNS, pulmonary, and urinary tract system.

FORMS

brand 
name
 
generic 
Mfg 
brand 
forms
 
cost* 
Fungizone  and genericAmphotericin B BMS  and generic manufacturers.IV 
vial
50 mg
$24.50 /50 mg vial

*Prices represent cost per unit specified and are representative of "Average Wholesale Price" (AWP). AWP Prices were obtained and gathered by Lakshmi Vasist Pharm D using the Red Book, manufacturer's information, and the McKesson database.

^Dosage is indicated in mg unless otherwise noted.

USUAL ADULT DOSING

Dosing range: 0.3-1.5 mg/kg/d IV (infuse over 2-4hrs). Oral form no longer commercially available.

  • Cryptococcal meningitis: 0.7mg/kg IV q24h +/- flucytosine 25mg/kg PO q6h x 2 wks, then fluconazole 400 mg PO q24h x 8 wks or until CSF is sterile. Maintenance therapy with fluconazole 200 mg PO q24h.
  • Candida esophagitis (azole-resistant): 0.3-0.7 mg/kg IV q24h (echinocandins can also be considered)
  • Systemic fungal infections: 0.5-1.5 mg/kg/d over 2-4 hrs w/ pre- and post-hydration. 

RENAL DOSING

DOSING FOR GLOMERULAR FILTRATION OF 50-80

Usual dose.

DOSING FOR GLOMERULAR FILTRATION OF 10-50

Usual dose. Consider alternative lipid formulation.

DOSING FOR GLOMERULAR FILTRATION OF <10 ML/MIN

If ARF reversible, consider alternative lipid formulation .

DOSING IN HEMODIALYSIS

Usual dose, no supplement needed post HD.

DOSING IN PERITONEAL DIALYSIS

Usual dose.

DOSING IN HEMOFILTRATION

No data. Usual dose likely.

ADVERSE DRUG REACTIONS

COMMON

  • Nephrotoxicity: can occur with or without nephrocalcinosis. Reduced with adequate hydration, salt loading (500 cc NS pre and post amphotericin B infusion) and avoidance of concurrent nephrotoxic agents.
  • Renal tubular acidosis.
  • Electrolyte abnormalities: hypokalemia, hypomagnesemia, and hypocalcemia.
  • Fever and chills: can be managed with meperidine or hydrocortisone 10-50 mg added to infusion. Alternatively, could premedicate with meperidine or ibuprofen.
  • Anemia (normocytic normochromic).
  • Phlebitis (improved with the addition of 1000 U heparin to infusion).
OCCASIONAL

  • Hypotension
  • Nausea and vomiting
  • Metallic taste
  • Headache

DRUG INTERACTIONS

  • Digoxin: may increase digitalis toxicity secondary to hypokalemia (consider potassium supplementation).
  • Diuretics and corticosteroids: may result in additive hypokalemia.
  • Nephrotoxic agents (e.g., foscarnet, cidofovir, aminoglycosides, and cyclosporine): may result in additive nephrotoxicity.

SPECTRUM

Broad-spectrum antifungal that includes: all . (except C. lusitaniae), Aspergillus spp., B. dermatitidis, C. immitis, C. neoformans, H. capsulatum, S. schenckii, and Zygomycetes.

RESISTANCE

  • Some spp. of Fusarium oxysporum and F. solani and most spp. of Pseudallescheria boydii are resistant.
  • Candida lusitaniae

PHARMACOLOGY

Pharmacology

COMMENTS

Use is complicated by high rate of infusion and dose-dependent related reactions such as anemia, electrolyte imbalance and renal failure. A switch to lipid formulation (liposomal amphotericin) generally recommended when serum creatinine elevated to arbitrary threshold (>2.5 used at Hopkins). Infusion-related side effects higher than Ambisome and Abelcet but lower than Amphotec. When indicated, alternative agents such as caspofungin may also be considered. Despite lower incidence of nephrotoxicity with lipid formulation, amphotericin B deoxycholate remains drug of choice for treatment of cryptococcal meningitis due to robust clinical data. For other invasive fungal infections, Ambisome and Abelcet generally preferred.

REFERENCES

REFERENCED WITHIN THIS GUIDE


 
Diagnosis
 


Complications of Therapy


Malignancies


Miscellaneous


Opportunistic Infections


Organ System

Drugs
 


Antimicrobial Agents


Antiretrovirals


Miscellaneous

Guidelines
 


Zambia HIV National Guidelines

Management
 


Antiretroviral Therapy


Laboratory Testing


Miscellaneous

Pathogens
 


Bacteria


Fungi


Parasites


Viruses

View All Modules
 
Index
 
 
Contacts    Help    Copyright    Acknowledgments    Abbreviations